TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04834258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking and respiratory training
Description: Walking and respiratory muscle training group ( W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training
Description: In the Respiratory muscle training group, Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged.
Study: NCT02515149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of care CD4 device (Alere PIMA)
Description: for persons testing + with home-based HIV testing using Kenya's two rapid test algorithm, intervention arm participants received point of care CD4 testing followed by counseling on results which included their treatment eligibility
Study: NCT01325727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief computerized feedback
Description: Brief computerized feedback
Study: NCT00068315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT02622295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-session electrically induced exercise
Description: A single session of electrically induced exercise to the quadriceps and hamstring muscle groups of people with paralysis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electrically-induced exercise training
Description: Multiple sessions of electrically induced exercise to the quadriceps and hamstring muscle groups for up to 3 years in people with paralysis.
Study: NCT01737983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri was administered in 5 drops per day (10\^10 colony-forming units) for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
Study: NCT02483858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQR 309
Description: Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
Study: NCT04033614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fasciotens-Abdomen
Description: The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
Study: NCT02688829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin target-eluting Coronary Stent System
Description: Implantation of the rapamycin-eluting coronary stent system
Study: NCT01009970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 day 1
Study: NCT04176757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5 study drug to be administered orally daily
Study: NCT01009970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 day 2
Study: NCT02034383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Controlled diet for 3 weeks with 0 servings/day of almonds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Almonds
Description: Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roasted Whole Almonds
Description: Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diced Almonds
Description: Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Butter
Description: Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
Study: NCT03564314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUPPORT AKI Clinical Decision Support
Description: Surgical units will receive a multidimensional clinical decision support intervention consisting of: (1) electronic and non-computerized tools to alert for early recognition of AKI, (2) educational program for physicians and nursing staff, (3) decision support tools with guidance on fluid therapies, medication management, investigations for AKI, and consultation with specialists.
Study: NCT01325727

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resources only (control)
Description: Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
Study: NCT02976324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external diaphragmatic pacemaker group
Description: 9 counts per minute, with stimulate frequency 40 Hz
Study: NCT01687426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate 0.025%
Description: 1 drop in each eye daily four times a day for 14 days
Study: NCT01009970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1,4 mg/m2 (max 2 mg) day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m2 day 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 day 2
Study: NCT03164252

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Grupo I- Lower laser fluency
Description: The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Grupo I- Lower laser fluency
Description: The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Grupo II- Greater laser fluency
Description: The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Grupo II- Greater laser fluency
Description: The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Grupo III- Laser sham
Description: The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Grupo III- Laser sham
Description: The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
Study: NCT01238471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: 2 mg per kg per day divided in 3 doses for 2-4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sucrose 5%
Description: 2 ml per Kg per day divided in 3 doses for 2-4 weeks
Study: NCT00476905

Intervention type: DEVICE
Intervention: Spectral Diagnosis Probe
Description: The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
Study: NCT04180579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAXMAN Scalp Cooler
Description: Scalp cooling will occur with each dose of chemotherapy.
Study: NCT03526406

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CP9700
Description: 400 mg CP9700 along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
Study: NCT03077711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim
Description: suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methenamine hippurate
Description: antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
Study: NCT02332876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT00650364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine HCl Tablets 5 mg
Description: 5mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAmatine® Tablets 5 mg
Description: 5mg, single dose fasting
Study: NCT03526406

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Maltodextrin along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
Study: NCT01841021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
Study: NCT00644514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin - lipopolysaccharide (LPS)
Description: Nebulized 5000EU, 10,000EU, 20,000EU endotoxin doses delivered to completion. Nebulized dose inhaled 30 minutes apart if no adverse events occur after the previous dose. Fiberoptic Bronchoscopy with Bronchoalveolar Lavage (BAL) and brush samples performed 24 hours after LPS nebulization.
Study: NCT04189302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue graft harvest using KPM blade
Description: after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using KPM blade.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft harvest using 15 C blade
Description: after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using 15C blade.
Study: NCT00507884

Intervention type: PROCEDURE
Intervention: 3 Tesla MRI Scan
Description: MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
Study: NCT01412736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4563
Description: every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4563
Description: every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4563
Description: every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
Study: NCT04025164

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: daily fractions, 2.66 Gy/3.2 Gy per fraction to whole breast/tumor bed, five fractions per week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fractionated Radiotherapy
Description: daily fractions, 2 Gy per fraction, five fractions per week
Study: NCT00104741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT01219790

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external radiotherapy
Description: All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acide zoledronic
Description: The administration of zoledronic acid as defined under the Authorisation on the Market.
Study: NCT01831011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mildronate injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinepazide maleate injection
Study: NCT00075855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic testosterone

Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Study: NCT00763295

Intervention type: OTHER
Intervention: T-Spot.TB test
Description: diagnostic test
Study: NCT01831011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Study: NCT01687426

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brimonidine Tartrate 0.025%
Description: 1 drop in each eye daily four times a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: 1 drop in each eye daily four times a day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop in each eye daily four times a day for 14 days
Study: NCT03878667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curves Calcium
Description: Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).
Study: NCT02972736

Intervention type: RADIATION
Intervention: Radiation dose expressed as DAP
Study: NCT03878667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curves Calcium
Description: Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curves Calcium
Description: Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curves Calcium
Description: Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium (providing 950 mg/d as carbonate)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium (providing 950 mg/d as carbonate)
Study: NCT02972736

Intervention type: RADIATION
Intervention: Radiation dose expressed as DAP

Intervention type: RADIATION
Intervention: Radiation dose expressed as DAP
Study: NCT03878667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium (providing 950 mg/d as carbonate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium (providing 950 mg/d as carbonate)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose placebo
Study: NCT01894776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
Study: NCT02945852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: apatinib 500mg/d until progressive Disease
Study: NCT01571167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
Study: NCT00732472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 7 day repeat dose
Study: NCT03557229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Oral: 50 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C 1 GM Oral Tablet
Description: Oral: 1 GM every 6 hours for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 UNT
Description: Oral: 400 UNT every 8 hours for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Oral: 1200 mg every 12 hours for 5 days
Study: NCT04272814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression therapy
Description: Compression application

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: initial clinical assessment
Description: Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: initial clinical assessment
Description: Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)
Study: NCT02762760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMPION™
Description: AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.